Deutetrabenazine - Teva Pharmaceutical
Alternative Names: AUSTEDO; AUSTEDO XR; d6-tetrabenazine; Deuterium-substituted tetrabenazine; Dutetrabenazine; SD-809; SD-809 ER; SD-809 Extended Release; TEV-50717Latest Information Update: 31 May 2024
At a glance
- Originator Auspex Pharmaceuticals
- Developer Auspex Pharmaceuticals; Nuvelution Pharma; Teva Pharmaceutical Industries
- Class Antipsychotics; Neuropsychotherapeutics; Organic deuterium compounds; Quinolizines; Small molecules
- Mechanism of Action Dopamine receptor antagonists; Dopamine release inhibitors; Vesicular monoamine transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chorea; Drug-induced dyskinesia
- Phase III Dyskinesias; Gilles de la Tourette's syndrome
Most Recent Events
- 29 May 2024 US FDA approves deutetrabenazine extended-release tablets (AUSTEDO XR) with four new tablet strengths ,,, 48 mg) for Drug-induced dyskinesia in USA
- 29 May 2024 US FDA approves deutetrabenazine extended-release tablets (AUSTEDO XR) with four new tablet strengths ,,, 48 mg) for Chorea associated with Huntington's disease in USA
- 26 Feb 2024 Jiangsu Nhwa and Teva Pharmaceuticals enter into a marketing agreement for commercialization of deutetrabenazine in China for Chorea and Dyskinesias